Navigation Links
BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
Date:12/29/2008

BOTHELL, Wash., Dec. 29 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has joined the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, an international consortium of leading scientific, clinical, and commercial partners whose mission is to explore collaborative ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy.

Zbigniew "Ziggy" M. Szczepiorkowski, MD, PhD, co-chair of the BEST cellular therapy team and Associate Professor of Pathology and of Medicine at Dartmouth Medical School, commented on the addition of BioLife Solutions as a new corporate member of BEST by stating, "We're very pleased to welcome BioLife to the BEST Collaborative. BioLife joins other corporate members in the quest to advance the field of transfusion medicine and to work with world leading experts. Results from recent initial safety studies conducted by BioLife and submission of FDA Master Files understandably elevates the profile of the company in the field of transfusion medicine in the US and internationally. We look forward to mutually beneficial scientific collaboration with BioLife and other BEST corporate members to identify ways to extend the shelf-life and improve the transportation logistics as well as post-preservation viability and functional yield of transfusion-related source material and derived cell-based clinical products."

Mike Rice, BioLife's chairman and CEO, noted "Since its formation, the scientific members of BEST have collectively published over 50 peer reviewed scientific articles related to efforts to continually improve quality, safety and efficiency in transfusion medicine. We view our relationship with BEST as highly strategic and a means to continue to demonstrate the scientific differentiation of our products and how they enable measurable improvement in several aspects of transfusion-related biopreservation processes."

About BioLife Solutions, Inc:

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit http://www.biolifesolutions.com.

About BEST Collaborative:

The BEST Collaborative is an international research organization that works collaboratively to explore ways to improve transfusion-related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy. The scientific members of BEST represent a broad diversity of interests and high levels of accomplishment. The manufacturer members of BEST span the gamut of companies engaged with blood collecting, processing, and transfusing organizations worldwide to provide a safe and adequate blood supply. For more information please visit http://www.bestcollaborative.org/.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

     Media Relations:                  Investor Relations:
     Len Hall                          Matt Clawson
     Allen & Caron Inc                 Allen & Caron Inc
     (949) 474-4300                    (949) 474-4300
     len@allencaron.com                matt@allencaron.com

'/>"/>
SOURCE BioLife Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
2. BioLife Solutions Granted European Biopreservation Patent
3. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
4. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
5. BioLife Solutions Credit Facility Increased to $9 Million
6. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
7. BioLife Solutions Outsourcing Manufacturing, Warehousing, and Order Fulfillment to Bioserv Corporation
8. BioLife Solutions CryoStor(TM) Adopted by Tissue Regeneration Therapeutics for Preservation Protocol for New, Non-Embryonic Source of Stem Cells
9. BioLife Solutions Expands Scientific Advisory Board
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. DuPont Acquires Ag Data Management Business to Enhance Information Solutions for Growers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for ... time. So which eye do you rinse first if a dangerous substance enters both eyes? ... Eye Wash with its unique dual eye piece. , “Whether its dirt and debris, ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):